Clinical Trial Update: Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II trial of lenalidomide for relapsed or refractory Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Disease

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hodgkin Disease | Phase 2 | Status: COMPLETED